Table 3.
Moderate-to-Severe AECOPDs During the Follow-Up Period (Non-Triple Therapy Users)
| Overall (n=9888) | ACL/FOR (n=2109) | IND/GLY (n=1785) | TIO/OLO (n=1189) | UMEC/VI (n=4805) | |
|---|---|---|---|---|---|
| 3 months post-index date | |||||
| Patients with ≥1 moderate-to-severe AECOPD, n (%) | 491 (5.0) | 117 (5.5) | 119 (6.7) | 45 (3.8) | 210 (4.4) |
| Per patient, mean (SD) | 0.05 (0.25) | 0.06 (0.27) | 0.07 (0.29) | 0.04 (0.22) | 0.05 (0.23) |
| Exacerbation rate, mean (SD) | 0.02 (0.11) | 0.02 (0.12) | 0.03 (0.13) | 0.02 (0.12) | 0.02 (0.10) |
| 6 months post-index date | |||||
| Patients with ≥1 moderate-to-severe AECOPD, n (%) | 845 (8.5) | 185 (8.8) | 195 (10.9) | 89 (7.5) | 376 (7.8) |
| Per patient, mean (SD) | 0.11 (0.39) | 0.12 (0.41) | 0.14 (0.45) | 0.09 (0.36) | 0.10 (0.37) |
| Exacerbation rate, mean (SD) | 0.02 (0.11) | 0.02 (0.11) | 0.03 (0.12) | 0.02 (0.12) | 0.02 (0.10) |
| 9 months post-index date | |||||
| Patients with ≥1 moderate-to-severe AECOPD, n (%) | 1089 (11.0) | 240 (11.4) | 241 (13.5) | 122 (10.3) | 486 (10.2) |
| Per patient, mean (SD) | 0.16 (0.51) | 0.17 (0.55) | 0.20 (0.58) | 0.14 (0.47) | 0.14 (0.47) |
| Exacerbation rate, mean (SD) | 0.02 (0.11) | 0.02 (0.11) | 0.03 (0.12) | 0.02 (0.12) | 0.02 (0.10) |
| 12 months post-index date | |||||
| Patients with ≥1 moderate-to-severe AECOPD, n (%) | 1304 (13.2) | 287 (13.6) | 287 (16.1) | 146 (12.3) | 584 (12.2) |
| Per patient, mean (SD) | 0.21 (0.63) | 0.22 (0.67) | 0.25 (0.71) | 0.18 (0.57) | 0.19 (0.59) |
| Exacerbation rate, mean (SD) | 0.02 (0.11) | 0.02 (0.11) | 0.03 (0.11) | 0.02 (0.12) | 0.02 (0.10) |
Abbreviations: ACL, aclidinium; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; FOR, formoterol fumarate; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; SD, standard deviation; TIO, tiotropium bromide; UMEC, umeclidinium; VI, vilanterol.